DEF: NeurAxis 2026 Annual Meeting Proxy Statement

NeurAxis, Inc. has issued its 2026 proxy statement detailing proposals for director elections, auditor ratification, and significant equity plan amendments.

Summary

• The 2026 Annual Meeting of Stockholders is scheduled for June 10, 2026, in Carmel, Indiana.
• Stockholders will vote on the election of six directors.
• The company seeks to ratify Rosenberg Rich Baker Berman, P.A. as the independent auditor for 2026.
• A proposal to amend the 2022 Omnibus Securities and Incentive Plan includes increasing authorized shares from 1,482,152 to 3,400,000 and extending the evergreen provision through 2033.
• Stockholders will vote on the approval of the 2025 Employee Stock Purchase Plan.
• As of the April 14, 2026 record date, there were 11,505,421 shares of Common Stock and 3,796,907 shares of Series B Preferred Stock outstanding.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing for an annual meeting, though the proposed significant increase in authorized shares for equity plans warrants investor scrutiny regarding potential dilution.

Positives

• The company is implementing an Employee Stock Purchase Plan to align employee interests with shareholders.
• The board maintains a majority of independent directors.
• The company has established clear committee structures (Audit, Compensation, Nominating and Corporate Governance) in compliance with NYSE American standards.

Negatives

• The company reported a net loss of $7,800,555 for the 2025 fiscal year.
• Significant dilution is proposed through the increase of authorized shares under the 2022 Omnibus Plan.
• The company has two demand notes receivable from founding shareholders totaling $1,012,800, which have been fully reserved as uncollectible.

Risks

• Continued net losses and reliance on equity-based compensation to attract and retain talent.
• Potential for future dilution of shareholder value due to the proposed increase in authorized shares.
• Dependence on a limited number of key personnel and potential conflicts of interest regarding related party transactions.
• The company's reliance on specific patents and the need for ongoing regulatory compliance.

Future Outlook

The company intends to continue its growth strategy by incentivizing key management and employees through expanded equity plans and the new Employee Stock Purchase Plan, while maintaining focus on its electro-therapy technology.

Management Comments

• The Board recommends voting FOR all proposals, including the election of directors and the amendment to the 2022 Omnibus Securities and Incentive Plan.
• Management emphasizes the importance of the 2022 Plan amendment to attract, retain, and motivate key employees and consultants.

Industry Context

StockSavvy.ai notes that NeurAxis is operating in the competitive medical device sector, where high R&D costs and net losses are common for early-stage commercialization companies. The focus on equity-based compensation is a standard mechanism for such firms to preserve cash while aligning management with long-term shareholder interests.

Comparison to Industry Standards

• The company's use of an evergreen provision in its incentive plan is consistent with many small-cap growth companies.
• The board composition and committee structure align with standard corporate governance practices for NYSE American-listed companies.

Corporate Governance

Related Party Transactions

• The company holds two fully reserved demand notes receivable from founding shareholders totaling $1,012,800.
• The company maintains an exclusive license agreement for certain patents with an entity owned by the CEO and Chief Regulatory Officer.
• The company sold NeuroStim devices at cost to a board member for R&D purposes.

Stakeholder Impact

• Shareholders face potential dilution from the proposed increase in authorized shares.
• Employees gain access to an Employee Stock Purchase Plan.
• Directors and officers receive continued equity-based compensation incentives.

Next Steps

• Hold the Annual Meeting on June 10, 2026.
• Implement the 2022 Plan amendment if approved by stockholders.
• Execute the 2025 Employee Stock Purchase Plan if approved by stockholders.

Key Dates

Recommendation

The filing is primarily administrative. While the equity plan expansion is significant, it is a standard corporate governance action. Investors should monitor the company's ability to reduce net losses and successfully commercialize its technology.

Keywords

NeurAxis, Proxy Statement, Annual Meeting, Equity Incentive Plan, Corporate Governance, Medical Device, Stockholder Voting